Endocrine Abstracts

Myeloperoxidase (MPO), an enzyme of the innate immune system, exhibits pro-atherogenic effects and includes influence on oxidative damage to LDL- and HDL-cholesterol, and promotion of endothelial dysfunction.

The aim: To investigate the disturbance of MPO in type 2 diabetic (T2D) patients depending on intensity of atherosclerosis

Material and methods: We investigated 244 patients aged from 45 to 60 years (M±SD 54.0±4.63) including 67 T2D patients treated with oral antidiabetic drugs with coronary artery disease; 88 patients with applications of coronary artery disease only and 89 healthy persons. The activity of MPO in plasma were estimated with special spectrophotometric method using O-dianisidine and MPO inhibitor hydraside 4-aminobenzoic acid. MPO concentration estimated with original IFA method with MPO antibodies from immunizated rats and rabbits.

Results: We revealed standart lipid abnormalities in examined patients. The MPO concentration in T2D were 46.9 (18.05–73.00) ng/ml to compare patients with control group 35.31 (19.30–84.40) ng/ml and patients without diabetes 40.20 (40.20–40.20) ng/ml. There were no difference of MPO activity: in T2D 0.0041 (0.008–0.010) EU; in healthy persons 0.0034 (0.001–0.007) EU and 0.0012 (0.001–0.001) EU in patients with applications of coronary artery disease.

Conclusions: T2D is not associated with higher concentration or activity of MPO.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.